Watson biosorption tetanus new vaccine completed clinical research

Watson biology announced in the evening of July 7 that its wholly-owned subsidiary Yuxi Watson "adsorbed tetanus vaccine" has completed the clinical research work, and recently received the "adsorbed tetanus vaccine clinical trial report" from Guangxi disease prevention and control center, the unit in charge of the clinical research, which shows that the research results achieved the expected efficacy Research and development of new vaccine products is one of the important strategies of Watson biology The completion of the clinical research means further research and development of new vaccine varieties of the company The previous week, the company announced that its clinical research application of "B paratyphoid combined vaccine" and "typhoid Vi polysaccharide combined vaccine" had been accepted by Yunnan food and drug administration It is understood that the company started the clinical field research in December 2009 Clinical trial evaluation: after the absorption of tetanus vaccine to children, there was no significant difference in the incidence of adverse events between the experimental vaccine group and the control vaccine group, the common adverse reactions were fever and local pain, and no serious adverse events related to vaccination were collected; the geometric average concentration of antibody in the experimental vaccine group was higher than that in the control vaccine group, and the antibody in the experimental vaccine group turned positive / 4 times The long-term rate was significantly higher than that of the control group The results of the study achieved the expected efficacy However, the clinical trial report of the adsorbed tetanus vaccine only shows that the product has completed the clinical research In the future, it is necessary to apply for the production approval of the product, obtain the production approval and the production workshop can be put into production after passing the GMP certification, and the product can be listed and sold only after the batch is issued Therefore, the event will not have an impact on the company's recent performance